1. Home
  2. SLDB vs ACTG Comparison

SLDB vs ACTG Comparison

Compare SLDB & ACTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLDB
  • ACTG
  • Stock Information
  • Founded
  • SLDB 2013
  • ACTG 1993
  • Country
  • SLDB United States
  • ACTG United States
  • Employees
  • SLDB N/A
  • ACTG N/A
  • Industry
  • SLDB Biotechnology: Biological Products (No Diagnostic Substances)
  • ACTG Multi-Sector Companies
  • Sector
  • SLDB Health Care
  • ACTG Miscellaneous
  • Exchange
  • SLDB Nasdaq
  • ACTG Nasdaq
  • Market Cap
  • SLDB 366.2M
  • ACTG 387.5M
  • IPO Year
  • SLDB 2018
  • ACTG 1996
  • Fundamental
  • Price
  • SLDB $3.65
  • ACTG $3.00
  • Analyst Decision
  • SLDB Strong Buy
  • ACTG
  • Analyst Count
  • SLDB 9
  • ACTG 0
  • Target Price
  • SLDB $15.67
  • ACTG N/A
  • AVG Volume (30 Days)
  • SLDB 1.3M
  • ACTG 357.3K
  • Earning Date
  • SLDB 05-14-2025
  • ACTG 05-08-2025
  • Dividend Yield
  • SLDB N/A
  • ACTG N/A
  • EPS Growth
  • SLDB N/A
  • ACTG N/A
  • EPS
  • SLDB N/A
  • ACTG N/A
  • Revenue
  • SLDB N/A
  • ACTG $122,312,000.00
  • Revenue This Year
  • SLDB N/A
  • ACTG $86.80
  • Revenue Next Year
  • SLDB $569.02
  • ACTG N/A
  • P/E Ratio
  • SLDB N/A
  • ACTG N/A
  • Revenue Growth
  • SLDB N/A
  • ACTG N/A
  • 52 Week Low
  • SLDB $2.45
  • ACTG $2.70
  • 52 Week High
  • SLDB $10.99
  • ACTG $5.74
  • Technical
  • Relative Strength Index (RSI)
  • SLDB 49.73
  • ACTG 38.41
  • Support Level
  • SLDB $2.48
  • ACTG $2.80
  • Resistance Level
  • SLDB $2.88
  • ACTG $3.14
  • Average True Range (ATR)
  • SLDB 0.31
  • ACTG 0.18
  • MACD
  • SLDB 0.10
  • ACTG 0.03
  • Stochastic Oscillator
  • SLDB 86.97
  • ACTG 54.63

About SLDB Solid Biosciences Inc.

Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.

About ACTG Acacia Research Corporation (Acacia Tech)

Acacia Research Corp is focused on acquiring and operating businesses across the industrial, energy, and technology sectors where it believes it can leverage its expertise, significant capital base, and deep industry relationships to drive value. Acacia evaluates opportunities based on the attractiveness of the underlying cash flows, without regard to a specific investment horizon. Acacia operates its businesses based on three key principles of people, process, and performance and has built a management team with demonstrated expertise in research, transactions and execution, and operations and management.

Share on Social Networks: